RxDoctor Payments Data

Michael Simmons, MD

Ophthalmology · Salt Lake City, UTNPI 1194256479

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 58.0% of the total. Reporting peaked in 2022 at $1,701 and has fallen 73.7% since, to $447 in 2025.

$2,952in general payments, 2019–2025

Across 63 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$499
  • Genentech USA, Inc.$236
  • Astellas Pharma US Inc$199
  • Glaukos Corporation$109
  • Alcon$85
  • plus $111 from 5 others
$11,100in research payments, 2019–2025

Across 287 payments — averaging $38.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$11K

What the payments were for

  • Travel & lodging$1,22742%
  • Food & beverage$1,71358%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,952 in reported general payments places this provider in the 75th percentile of 191 ophthalmology providers in Utah.

See all ophthalmology providers in Utah

Medicare billing

Part B allowed, 2024
$3,257,433
Medicare patients
536
Services billed
14,177

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate63$2,635
Ketorolac Tromethamine19$496
MoxifloxacinMoxifloxacin Hcl17$372
Latanoprost45$273
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim21$177
Dorzolamide Hcl13$158
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$97
Brimonidine Tartrate11$79

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →